June 24–26, 2027, Rome, Italy

Talk Details · Heart Congress 2026

Current approaches to anti-angina drug treatment in Chronic-stable Angina Pectoris (CSAP) in US primary care and cardiology – A cross-sectional, blinded standard-of-care survey

Oral · Day 1

Abstract

About this talk

Background: Availability and use recommendations of anti-anginals in chronic-stable angina pectoris (CSAP) has changed little since the last anti-anginal was FDA approved in 2006. Recent large outcomes studies have changed consensus on management of CSAP. Guidelines again focus on drug treatment for most pts. With new anti-anginals in development it seems prudent to investigate management approaches to CSAP in primary care and cardiology.

Methods: Perceived disease burden, similarities & differences in treatment with available anti- angina drug portfolio and impact of select comorbid conditions was studied comparing 30 cardiology (CARD) vs 30 internal medicine (IM) participants (demographics: Fig.1). Eligible participants were board-certified, actively managing CSAP patients (caseload ≥30 and ≥25 pts.). The survey comprised 30 questions assessing demographics, patient characteristics, diagnostic approaches, and treatment initiation & maintenance patterns. Responses were anonymized and collected between Jul and Aug 2025. Evaluable information was available for all 60 physicians.

Results: Baseline patient demographic data confirms representative patient pool: 56% male, estimated age 60-70y for most (65%), and weekly angina symptoms in 45% of pts. For key survey output data see Fig. 1.

Conclusion: There is agreement between CARDs and IMs on treatment goals, utility of antianginals, assessment and core drivers of refractory angina, impact of CMD as a comorbidity and its treatment- complicating effect. Treatment initiation with 2 antianginals is common despite UIS guideline recommendations to the contrary. Differences exist between antianginal drug choices and comorbidity prevalence estimates.

Speaker

About the speaker

Uwe Peter Tigor

Uwe Peter Tigor

Auxilius Pharma, United States

View full speaker profile →

Join the Heart Congress 2027 delegation

Rome · June 24–26, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.

Chat with us